Starpharma to establish UK joint venture

Pharmaceutical company Starpharma is to establish a new UK based company called Petalion Therapeutics Limited in joint venture with life sciences investment firm Medicxi,. Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies in oncology, utilising Starpharma’s proprietary DEP dendrimer platform technology. Medicxi will fund Petalion with an initial investment of up to…

Starpharma, UQ target new radiopharmaceuticals

A federal government science grant and industry funding has sparked the creation of a new research and industry hub targeting the development of new radiopharmaceuticals. Pharmaceutical developer Starpharma has partnered with the University of Queensland and the University of Sydney in establishing the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub). Backed…

Starpharma’s Covid-killer needs action not bureaucracy from TGA

By Peter Roberts I have nothing but the deepest respect for Australia’s Therapeutic Goods Administration, but a certain lack of initiative on the part of the TGA seems to be preventing Australians from getting access to the latest Australian-developed tools to fight Covid-19. Make no mistake the TGA has an exemplary record in regulating Australians’…

Starpharma launches Viraleze in the UK

Pharmaceutical developer Starpharma has secured United Kingdom distribution for its Viraleze antiviral nasal spray. The Melbourne company has signed a sales and distribution agreement with LloydsPharmacy which operates 1,400 pharmacy stores in the UK and is part of international pharma distributor group McKesson. McKesson supplies more than 14,000 pharmacies across the UK. Viraleze spray, which…